» Articles » PMID: 22630149

Gold Nanoparticles As Carriers for a Synthetic Streptococcus Pneumoniae Type 14 Conjugate Vaccine

Overview
Specialty Biotechnology
Date 2012 May 29
PMID 22630149
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Coupling of capsular polysaccharides of pathogens to immunogenic protein carriers (conjugate vaccines) improves carbohydrate immune response. Our idea is to explore gold nanoclusters as carriers to prepare fully synthetic carbohydrate vaccines.

Materials & Methods: Gold glyconanoparticles bearing a synthetic tetrasaccharide epitope related to the Streptococcus pneumoniae type 14 capsular polysaccharide (Pn14PS), the T-helper ovalbumin 323-339 peptide (OVA(323-339)), and D-glucose were prepared by a one-pot method. Their immunogenicity was tested in mice. Cytokine levels after spleen cell stimulation with OVA(323-339) were analyzed using a luminex-multiplex cytokine assay. The capacity of the evoked antibodies to promote the uptake of S. pneumoniae type 14 by leukocytes was assessed.

Results & Discussion: Glyconanoparticles containing 45% of tetrasaccharide and 5% OVA(323-339) triggered specific anti-Pn14PS IgG antibodies. Cytokine levels confirmed that glyconanoparticles led to T-helper cell activation. The anti-saccharide antibodies promoted the phagocytosis of type 14 bacteria by human leukocytes, indicating the functionality of the antibodies.

Conclusion: Gold nanoparticles have great potential as carriers for the development of a great diversity of fully synthetic carbohydrate-based vaccines.

Citing Articles

Monosaccharide coating modulate the intracellular trafficking of gold nanoparticles in dendritic cells.

Alobaid M, Richards S, Alexander M, Gibson M, Ghaemmaghami A Mater Today Bio. 2024; 29:101371.

PMID: 39698001 PMC: 11652954. DOI: 10.1016/j.mtbio.2024.101371.


Analysis of immunogenicity and purification methods in conjugated polysaccharide vaccines: a new approach in fighting pathogenic bacteria.

Sheikhi A, Shirmohammadpour M, Mahdei Nasirmahalleh N, Mirzaei B Front Immunol. 2024; 15:1483740.

PMID: 39635523 PMC: 11614811. DOI: 10.3389/fimmu.2024.1483740.


Nanoparticles as Delivery Systems for Antigenic Saccharides: From Conjugation Chemistry to Vaccine Design.

Archambault M, Tshibwabwa L, Cote-Cyr M, Moffet S, Shiao T, Bourgault S Vaccines (Basel). 2024; 12(11).

PMID: 39591192 PMC: 11598982. DOI: 10.3390/vaccines12111290.


Semisynthetic Pneumococcal Glycoconjugate Nanovaccine.

Prasanna M, Varela Calvino R, Lambert A, Arista Romero M, Pujals S, Trottein F Bioconjug Chem. 2023; 34(9):1563-1575.

PMID: 37694903 PMC: 10515484. DOI: 10.1021/acs.bioconjchem.3c00252.


Nanobiotics against antimicrobial resistance: harnessing the power of nanoscale materials and technologies.

Chakraborty N, Jha D, Roy I, Kumar P, Singh Gaurav S, Marimuthu K J Nanobiotechnology. 2022; 20(1):375.

PMID: 35953826 PMC: 9371964. DOI: 10.1186/s12951-022-01573-9.